Psychiatry

Back to articles

Ziprasidone: Less Weight Gain, But QTc Interval Prolonged

KEY POINT

Although Pfizer’s ziprasidone, a new agent for the treatment of schizophrenia, is less likely to cause weight gain than other antipsychotic agents, it is more likely to prolong the QTc interval and could therefore put patients at risk for torsades de pointes and other potentially fatal ventricular arrhythmias.

SOURCES

Hensley S. Schizophrenia drug from Pfizer wins FDA approval. Wall Street Journal. February 6, 2001:B21.

Anonymous. Pfizer ziprasidone labeling stops short of second-line use; QT effect noted. FD&C Reports:The Pink Sheet. February 12, 2001:9–10.